A Review on Nanocarriers Third Generation As Targeted Delivery Systems for Cancer Therapy | Zendy

Rajappa Margret Chandira | Zendy; Balaashwin Babu | Zendy; B. S. Venkateswarlu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Review on Nanocarriers Third Generation As Targeted Delivery Systems for Cancer Therapy

Author(s) -

Rajappa Margret Chandira,

Balaashwin Babu,

B. S. Venkateswarlu

Publication year - 2021

Publication title -

american journal of pharmacy and health research

Language(s) - English

Resource type - Journals

ISSN - 2321-3647

DOI - 10.46624/ajphr.2021.v9.i10.001

Subject(s) - nanocarriers , drug delivery , nanotechnology , nanomedicine , cancer therapy , targeted drug delivery , cancer , medicine , targeted therapy , risk analysis (engineering) , materials science , nanoparticle

Cancer is a leading cause of death worldwide. Currently available therapies are inadequate and spur demand for improved technologies. Nanomaterials are at the cutting edge of the rapidly developing area of nanotechnology. The potential for nanoparticles in cancer drug delivery is infinite with novel new applications constantly being explored. Targeted nanoparticles play a very significant role in cancer drug delivery. The promising implications of these platforms for advances in cancer diagnostics and therapeutics form the basis of this review. Targeted delivery systems of nano biomaterials are necessary to be developed for the diagnosis and treatment of cancer. Nano-based pharmaceuticals, or nanomedicines,” are engineered to either function as a drug or carry a drug while addressing these scientific challenges due to their nano-size. Keywords: Nanomaterials, nanomedicines, Targeted delivery

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research